N/A
Manufactured by sanofi-aventis U.S. LLC
19,263 FDA adverse event reports analyzed
Last updated: 2026-04-14
INSULIN GLULISINE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by sanofi-aventis U.S. LLC. The most commonly reported adverse reactions for INSULIN GLULISINE include BLOOD GLUCOSE INCREASED, HYPOGLYCAEMIA, HYPERGLYCAEMIA, DRUG INEFFECTIVE, BLOOD GLUCOSE DECREASED. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for INSULIN GLULISINE.
Out of 9,945 classified reports for INSULIN GLULISINE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 19,263 FDA FAERS reports that mention INSULIN GLULISINE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include BLOOD GLUCOSE INCREASED, HYPOGLYCAEMIA, HYPERGLYCAEMIA, DRUG INEFFECTIVE, BLOOD GLUCOSE DECREASED, DIZZINESS. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list sanofi-aventis U.S. LLC in connection with INSULIN GLULISINE. Always verify the specific product and NDC with your pharmacist.